So the honest answer to the tirzepatide tablet question is nuanced: no approved branded tablet exists, but oral GLP-1 options do, each with its own rules and trade-offs
Tirzepatide is a once-weekly, dual-incretin peptide it activates both the GIP and the GLP-1 receptor from a single molecule and in published obesity trials it has produced some of the largest average weight reductions of any incretin agent studied to date
The patient does not have type 2 diabetes (patients with type 2 diabetes and cardiovascular disease should be considered for Ozempic, which is indicated for this use), and
Variants in the FTO gene (rs9939609) and MC4R gene (rs17782313) affect baseline metabolism and appetite regulation, meaning two people on identical tirzepatide doses may experience different timelines
Regarding tolerability, evidence indicates that GLP-1RAs are safe for non-diabetic obese patients
Global Heart 2017, 12: 341-348